ArticleBMC musculoskeletal disorders2025
LINC00662 regulates osteogenic differentiation of BMSCs and inhibits fracture healing via miR-330-3p/PTEN axis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical treatment alone is not effective in addressing delayed fracture healing (DFH). This study nvestigates the molecular mechanism underlying fracture healing to identify improved therapeutic strategies.
methodsSerum samples were collected from 76 normal fracture healing (NFH) and 70 DFH patients. RT-qPCR was performed to determine LINC00662, miR-330-3p, and PTEN mRNA expression in serum and Human Bone marrow mesenchymal stem cells (HBMSCs). The diagnostic potential of LINC00662 and miR-330-3p for DFH patients was evaluated via ROC analysis. Binding sites were predicted using bioinformatic databases and validated by dual-luciferase reporter assays. HBMSCs proliferation, apoptosis and osteogenic differentiation were analyzed using CCK-8, flow cytometry, andosteogenesis-related gene expression assays.
resultsLINC00662 was upregulated and miR-330-3p downregulated in DFH, and the two combined could efficiently diagnose DFH. LINC00662 knockdown promoted runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), osteopontin (OPN), and alkaline phosphatase (ALP) mRNA expression, enhanced HBMSCs proliferation, and suppressed apoptosis. miR-330-3p inhibition reversed these effect. As a target of miR-330-3p, PTEN downregulation ameliorated the negative effects of miR-330-3p downregulation on HBMSCs.
conclusionLINC00662 and miR-330-3p synergistically could improve the diagnostic efficiency of DFH. LINC00662 impedes fracture healing by suppressing osteogenic differentiation and proliferation of HBMSCs while promoting apoptosis in HBMSCs via the miR-330-3p/PTEN axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.